1
|
Wang K, Lü H, Qu H, Xie Q, Sun T, Gan O, Hu B. miR-492 Promotes Cancer Progression by Targeting GJB4 and Is a Novel Biomarker for Bladder Cancer. Onco Targets Ther 2019; 12:11453-11464. [PMID: 31920334 PMCID: PMC6935362 DOI: 10.2147/ott.s223448] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2019] [Accepted: 12/07/2019] [Indexed: 12/24/2022] Open
Abstract
Background Bladder cancer is the most common urinary system malignancy in the United States and is characterized by its diverse prognosis and high recurrence rate. However, the molecular mechanisms underlying its progression remain unknown. Accumulating evidence suggests a critical role for miRNAs in bladder cancer progression. Methods and results In this study, we found that miR-492 expression levels were significantly higher in bladder cancer tissue and the serum of bladder cancer patients by bioinformatics analysis and a panel of clinical samples. The results of receiver operating characteristic curve analysis suggested the potential diagnostic value of serum miR-492 for bladder cancer. In vitro and in vivo functional assays showed that knockdown of miR-492 suppressed proliferation and metastasis of bladder cancer cells. Gap junction beta-4 protein was predicted to be a direct target of miR-492, which was validated using a luciferase reporter assay. Further cellular functional assays showed that suppression of miR-492 abrogated bladder cancer cell proliferation and metastasis by targeting gap junction beta-4 protein. Conclusion miR-492 promotes cancer progression by targeting GJB4 and is a novel biomarker for bladder cancer.
Collapse
Affiliation(s)
- Kai Wang
- Department of Urology Surgery, Liaoning Province Cancer Hospital and Institute (Cancer Hospital of China Medical University), Shenyang 110004, People's Republic of China
| | - Hang Lü
- Department of Urology Surgery, Liaoning Province Cancer Hospital and Institute (Cancer Hospital of China Medical University), Shenyang 110004, People's Republic of China
| | - Hongchen Qu
- Department of Urology Surgery, Liaoning Province Cancer Hospital and Institute (Cancer Hospital of China Medical University), Shenyang 110004, People's Republic of China
| | - Qingpeng Xie
- Department of Urology Surgery, Liaoning Province Cancer Hospital and Institute (Cancer Hospital of China Medical University), Shenyang 110004, People's Republic of China
| | - Tao Sun
- Department of Urology Surgery, Liaoning Province Cancer Hospital and Institute (Cancer Hospital of China Medical University), Shenyang 110004, People's Republic of China
| | - Ou Gan
- Department of Urology Surgery, Liaoning Province Cancer Hospital and Institute (Cancer Hospital of China Medical University), Shenyang 110004, People's Republic of China
| | - Bin Hu
- Department of Urology Surgery, Liaoning Province Cancer Hospital and Institute (Cancer Hospital of China Medical University), Shenyang 110004, People's Republic of China
| |
Collapse
|
2
|
Peng S, Huang GL, Xu N, Lu Y, Zeng L, Li X, Luo S, Lyu X, Jiang Q, Li T, He Z. The human ATF1 rs11169571 polymorphism associated with risk of nasopharyngeal carcinoma in Southern Chinese populations. Cancer Med 2019; 8:1893-1898. [PMID: 30905073 PMCID: PMC6488110 DOI: 10.1002/cam4.2022] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2018] [Revised: 01/08/2019] [Accepted: 01/16/2019] [Indexed: 12/12/2022] Open
Abstract
Our previous work reported activating transcription factor 1 (ATF1) is a promotive factor of nasopharyngeal carcinoma (NPC) tumorigenesis. This study is to further explore the association between the human ATF1 rs11169571 polymorphism and the risk of NPC occurrence. The association between ATF1 rs11169571 and risk of NPC occurrence was investigated in clinical samples of 560 patients and 661 controls obtained from southern China with high incidence of NPC. The genotypes were detected by PCR‐RFLP. The differential expression activity of alleles ‐T and ‐C was analyzed with CNE‐2 and C666‐1 cells by luciferase reporter assay. Our data suggested that the allelic frequency and genotypes were significantly different between patients and controls. Compared to the TT homozygote, the TC and CC genotypes have been shown to be significantly decreased in NPC patients (OR = 0.494, 95% CI = 0.387‐0.629, P < 0.001 and OR = 0.556, 95% CI = 0.364‐0.851, P = 0.007, respectively). Compared to the ‐T allele, the ‐C allele is a factor of decreased risk in NPC (OR = 0.642, 95% CI = 0.537‐0.767, P < 0.001). Luciferase reporter activity revealed that the ‐T allele confers a higher expression activity than the ‐C allele in CNE2 cells and C666‐1 cells. In conclusion, ATF1 rs11169571 which could affect the expression of ATF1 is associated with NPC risk.
Collapse
Affiliation(s)
- Shutang Peng
- China-American Cancer Research Institute, Dongguan Scientific Research Center, Guangdong Medical University, Dongguan, China.,Key Laboratory for Epigenetics of Dongguan City, Dongguan, China.,Key Laboratory for Medical Molecular Diagnostics of Guangdong Province, Dongguan, China
| | - Guo-Liang Huang
- China-American Cancer Research Institute, Dongguan Scientific Research Center, Guangdong Medical University, Dongguan, China.,Key Laboratory for Epigenetics of Dongguan City, Dongguan, China.,Key Laboratory for Medical Molecular Diagnostics of Guangdong Province, Dongguan, China
| | - Nansong Xu
- China-American Cancer Research Institute, Dongguan Scientific Research Center, Guangdong Medical University, Dongguan, China.,Key Laboratory for Epigenetics of Dongguan City, Dongguan, China.,Key Laboratory for Medical Molecular Diagnostics of Guangdong Province, Dongguan, China
| | - Yan Lu
- China-American Cancer Research Institute, Dongguan Scientific Research Center, Guangdong Medical University, Dongguan, China.,Key Laboratory for Epigenetics of Dongguan City, Dongguan, China.,Key Laboratory for Medical Molecular Diagnostics of Guangdong Province, Dongguan, China
| | - Liuyan Zeng
- Department of Health Management Center, The Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
| | - Xin Li
- Cancer Research Institute, Southern Medical University, Guangzhou, China
| | - Shengqun Luo
- China-American Cancer Research Institute, Dongguan Scientific Research Center, Guangdong Medical University, Dongguan, China.,Key Laboratory for Epigenetics of Dongguan City, Dongguan, China.,Key Laboratory for Medical Molecular Diagnostics of Guangdong Province, Dongguan, China
| | - Xiaoming Lyu
- Department of Laboratory Medicine, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
| | - Qiang Jiang
- Cancer Research Institute, Southern Medical University, Guangzhou, China
| | - Tong Li
- China-American Cancer Research Institute, Dongguan Scientific Research Center, Guangdong Medical University, Dongguan, China.,Key Laboratory for Epigenetics of Dongguan City, Dongguan, China.,Key Laboratory for Medical Molecular Diagnostics of Guangdong Province, Dongguan, China
| | - Zhiwei He
- China-American Cancer Research Institute, Dongguan Scientific Research Center, Guangdong Medical University, Dongguan, China.,Key Laboratory for Epigenetics of Dongguan City, Dongguan, China.,Key Laboratory for Medical Molecular Diagnostics of Guangdong Province, Dongguan, China
| |
Collapse
|